Efficacy and Safety of HRS-7535 Tablets in Obese Subjects .

Prior treatment

• Presence of clinically significant lab or ECG results that may affect the evaluation of the efficacy or safety of the study drug at screening visit;
• History of acute cardiovascular and cerebrovascular diseases within 6 months prior to screening;
• Use of any medication or treatment that may have caused significant weight change within 2 months;
• history of blood donation or blood loss in the 3 months before screening, or blood transfusion in the 2 months before screening;
• Surgery is planned during the trial;

Other illness

• Uncontrollable hypertension;
• History of diabetes;
• Any organ-system malignancies developed within 5 years except for cured local basal cell cancer of the skin and in-situ cancer of the cervix;
• Confirmed or suspected depression, bipolar disorder, suicidal tendencies, schizophrenia, or other serious mental illness;
• History of bariatric surgery;

Other

• PHQ-9 score ≥15;
• Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using an adequate contraceptive method;
• Researchers and relevant staff of the research Centre or other people directly involved in the implementation of the programme, and their immediate family members.

• Male or female subjects, 18-65 years of age at the time of signing informed consent;
• At screening and random visit, 28.0 ≤BMI≤ 40.0 kg/m2;
• Diet and exercise control for at least 3 months before screening and random visit, and less than 5 % self-reported change within the last 3 months.
• Able and willing to provide a written informed consent